ChemPartner
22.12.2023 22:02:41 CET | ACCESS Newswire | Press release
Newly-launched database offers easier access to diverse tumor models and unveils the path to pharmaceutical breakthroughs
SHANGHAI, CHINA / ACCESSWIRE / December 22, 2023 / ChemPartner, a global leader in drug discovery and development services, today announced the launch of its long-awaited Biology Database. This innovative platform serves as a centralized hub, empowering ChemPartner's clientele with seamless access to a wealth of information on the organization's cutting-edge preclinical platforms. The database includes 800+ tumor models, 30+ cancer types, 20,000 genes, 2,300+ pathways, 1,800 SoC data from literature (500 internal), and 30+ analytic modules.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Screenshot of the online Biology Database from ChemPartner
ChemPartner's renowned biology and pharmacology department, known for its vanguard oncology, immunology, CNS, and metabolic services, has curated an extensive collection of in vitro and in vivo models. The database boasts over 2,000 biochemistry assays, 800 cell lines, 500 patient-derived xenograft (PDX) models, 350 cell-derived xenograft (CDX) models, and 50 syngeneic models. Each model is meticulously characterized with comprehensive data encompassing genomics, pharmacology, histopathology, and relevant clinical information.
Cell Line Models - ChemPartner Biology Database
To ensure a smooth and efficient rollout of this substantial volume of data, the database will be introduced in stages. We are delighted to announce that the first stage, featuring cell line data, is now live on https://database.chempartner.com. Subsequent stages will include CDX, syngeneic, and PDX models, followed by biochemistry data.
The Biology Database, a flagship online collaborative platform, prominently features the Tumor Model Database. This revolutionary resource offers an array of features, including:
- Unified Data Hub: Integration of dispersed tumor model data into a centralized database for efficient management and retrieval, simplifying user access to diverse tumor models.
- Detailed Annotations: Each model is accompanied by intricate annotations including genomics, pathology, and pharmacology data, enabling rapid understanding of model characteristics and suitability for specific research needs.
- Rapid Search and Filtering: Multidimensional search and filtering capabilities empower researchers to swiftly locate models based on cancer type, genomic features, drug sensitivity, and more.
- Data Analysis and Mining: Robust tools facilitate tasks like drug mechanism analysis and biomarker discovery through differential gene expression and drug sensitivity analyses, supporting informed research decisions.
- Data Visualization: Intuitive charts, statistics, and visualization tools present complex data clearly and concisely, aiding in model selection and analysis.
Dr. Lilly Xu, President of Shanghai ChemPartner, expressed enthusiasm about the launch saying, "We are excited to provide our customers with access to this powerful new resource. This comprehensive database will make it easier for our customers to find and use the right models for their research, propelling drug development towards new heights with better precision, efficacy, and efficiency."
-
About ChemPartner
ChemPartner is a leading global CRO and CDMO providing drug discovery, development, and manufacturing services to the pharmaceutical and biotechnology industries. With a team of over 2,000 scientists across multiple countries, ChemPartner offers a comprehensive range of services including preclinical pharmacology, toxicology, drug metabolism and pharmacokinetics, chemistry development, and biologics development. For more information, please visit https://chempartner.com and connect with ChemPartner on LinkedIn, X, and YouTube.
Contact Information
Sarah Stapleton
Marketing Director
news@chempartner.com
6504199974
Related Images
|
SOURCE: ChemPartner
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Global Experts call for Paradigm Shift in Medicine, Health and Education to Save Lives and Fight Escalating Health Crisis1.5.2026 14:48:00 CEST | Press release
INNSBRUCK, AUSTRIA / ACCESS Newswire / May 1, 2026 / A global consortium of 64 experts (72 entities, 5 continents) unveiled two coordinated consensus plus policy brief reports, outlining a science‑driven roadmap to confront escalating health crises and to tackle the growing burden of noncommunicable diseases (NCDs-including cardiovascular diseases, cancer, diabetes, etc.: 75% of global deaths; 82% in low-/middle income countries; 90% of all death in European region). The centerpiece is HEAL-Healthy Eating & Active Living, ideally whole‑food plant‑predominant/vegetarian-vegan diets & daily exercise outdoors/active mobility-as the minimum, first‑line standard in health and care. The authors urge immediate action on Prevention-over-Treatment and reforming education and human‑relevant science (drug failure rate from animal studies is 90-95%, and as high as 99.6% for Alzheimer disease), with a rapid shift from disease‑centered reaction to person‑centered, lifestyle‑first cure and care. Figu
Datavault AI and CyberCatch Announce Signing of Binding Letter of Intent for Datavault AI to Acquire CyberCatch to Accelerate AI-Driven, Quantum-Resistant Cyber Risk Mitigation Solutions1.5.2026 14:00:00 CEST | Press release
Strategic acquisition is anticipated to position Datavault AI to bring CyberCatch's AI-enabled cyber risk mitigation solution into Datavault AI's SanQtum-secured edge Graphics Processing Unit ecosystem, addressing a global information security market projected to reach $240 billion in 2026 (Gartner) CyberCatch's post-quantum cryptography conversion plan is also expected to position the combined company ahead of the AI-enabled "Q-Day" quantum-attack horizon, now compressed to as early as 2029 (Google) AI-enabled adversary attacks in 2025 rose 89% year-over-year while average eCrime breakout time fell to 29 minutes, a 65% increase in adversary speed compared to 2024, per CrowdStrike's 2026 Global Threat Report, and Google Quantum AI research has now compressed the timeline for cryptographically relevant quantum computing to as early as 2029. PHILADELPHIA, PA AND SAN DIEGO, CA / ACCESS Newswire / May 1, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider o
Securitas Healthcare Acquires ZulaFly(TM) to Advance Cloud-Based RTLS and Accelerate Innovation Across Healthcare1.5.2026 14:00:00 CEST | Press release
LINCOLN, NE / ACCESS Newswire / May 1, 2026 / Securitas Healthcare, a leading provider of real‑time visibility and protection solutions for the healthcare industry, is proud to announce the acquisition of ZulaFly, a healthcare‑focused Real‑Time Location System (RTLS) and staff safety technology company known for its modern, cloud‑based platform. ZulaFly's cloud-based RTLS platform delivers real-time visibility and actionable insights through a flexible, data-driven architecture. Built as a single SOC 2 Type II-compliant instance, ZulaFly offers an intuitive user experience, easy configuration, standardized data models, centralized analytics, and simplified system management. This approach enables healthcare organizations to deploy faster, gain insights sooner, and reduce long-term total cost of ownership (TCO). "This acquisition aligns with our focus and commitment to delivering best‑in‑class RTLS solutions across both cloud-based and on-premise options, keeping our healthcare clients
Datavault AI Schedules Conference Call to Discuss First Quarter 2026 Financial Results on Friday, May 15, 202630.4.2026 21:00:00 CEST | Press release
PHILADELPHIA, PA / ACCESS Newswire / April 30, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real‑world asset ("RWA") tokenization technologies, today announced that it will report financial results for its first quarter of 2026 prior to market open on Friday, May 15, 2026. Following the release, Datavault AI will host a conference call and live webcast on the same day, at 8:30 a.m. ET. Conference Call and Webcast Information Date: Friday, May 15, 2026, at 8:30 a.m. ET Participant Dial-in (US): 1-877-709-8150 Participant Dial-in (International): 1-201-689-8354 -- or Click HERE for participant International Toll-Free access numbers Webcast Access: Click Here Datavault AI CEO, Nathaniel Bradley, and CFO Brett Moyer, will be presenting. A replay of the webcast will be made available later in the day in the Investors/Presentations section of the Datavault AI website: Click Here About Datavau
POLARIS Laboratories Expands Globally with Acquisition of UK-Based Oil Check Laboratory Services30.4.2026 20:42:00 CEST | Press release
POLARIS Laboratories® acquires Oil Check Laboratory Services LTD (OCLS), a strategic step in supporting growing industries, markets and key global customers. INDIANAPOLIS, IN / ACCESS Newswire / April 30, 2026 / POLARIS Laboratories® announces the acquisition of Oil Check Laboratory Services Ltd (OCLS), a well-established fluid analysis laboratory headquartered in Doncaster, United Kingdom. The transaction represents a strategic step in POLARIS Laboratories' expansion into supporting new markets including data centers, power generation and transformer oils, enhancing its international presence and strengthening its ability to serve customers across key global markets. OCLS is recognized for its high-quality lubricant and diesel fuel testing, as well as condition monitoring services, supporting a diverse base of industrial and mobile equipment applications. The combination of companies brings together complementary technical capabilities, increased testing capacity, and an expanded regi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom